Revenue: As of FY2025 Q2, the actual value is USD 797.4 M.EPS: As of FY2025 Q2, the actual value is USD 0.05.EBIT: As of FY2025 Q2, the actual value is USD 11.9 M.<h3>BSI BioSpin</h3><ul><li>Revenue: $195.3 million, a decrease of 10.2% from $217.5 million in Q2 2024.</li><li>Gross Profit: $87.2 million, a decrease from $106.7 million in Q2 2024.</li><li>Gross Margin: 44.6%, down from 49.1% in Q2 2024.</li></ul><h3>BSI CALID</h3><ul><li>Revenue: $285.8 million, an increase of 7.6% from $265.6 million in Q2 2024.</li><li>Gross Profit: $137.2 million, an increase from $128.1 million in Q2 2024.</li><li>Gross Margin: 48.0%, slightly down from 48.2% in Q2 2024.</li></ul><h3>BSI NANO</h3><ul><li>Revenue: $252.1 million, a slight decrease of 0.2% from $252.5 million in Q2 2024.</li><li>Gross Profit: $112.1 million, a decrease from $115.7 million in Q2 2024.</li><li>Gross Margin: 44.5%, down from 45.8% in Q2 2024.</li></ul><h3>BEST</h3><ul><li>Revenue: $66.3 million, a decrease of 4.1% from $69.1 million in Q2 2024.</li><li>Gross Profit: $21.4 million, a decrease from $23.1 million in Q2 2024.</li><li>Gross Margin: 32.3%, down from 33.4% in Q2 2024.</li></ul><h3>Consolidated Results</h3><ul><li>Total Revenue: $797.4 million, a decrease of 0.4% from $800.7 million in Q2 2024.</li><li>Total Gross Profit: $357.9 million, a decrease from $384.6 million in Q2 2024.</li><li>Total Gross Margin: 44.9%, down from 48.0% in Q2 2024.</li></ul><h3>Operating Expenses</h3><ul><li>Selling, General and Administrative: $231.4 million, an increase of 4.6% from $221.3 million in Q2 2024.</li><li>Research and Development: $100.2 million, an increase of 8.7% from $92.2 million in Q2 2024.</li><li>Other Charges, Net: $14.4 million, a decrease from $23.0 million in Q2 2024.</li></ul><h3>Operating Income</h3><ul><li>Operating Income: $11.9 million, a decrease of 75.3% from $48.1 million in Q2 2024.</li><li>Operating Margin: 1.5%, down from 6.0% in Q2 2024.</li></ul><h3>Net Income</h3><ul><li>Net Income: $7.6 million, unchanged from Q2 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Provided by (Used in) Operating Activities: - $127.5 million, a decrease from $1.1 million in Q2 2024.</li><li>Free Cash Flow: - $148.8 million, a decrease from - $23.5 million in Q2 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to continue focusing on its core business areas, with structured strategic plans tied to measurable goals such as growth targets, margin improvement, and market expansion.</li><li>Non-Core Business: The company is also exploring emerging segments and divestitures, with a focus on clarity and actionability.</li><li>Priority: Emphasis is placed on strategies with concrete projections or quantitative indicators over generic or vague statements.</li></ul>

Bruker Corp Pref Shares BRKRP 6.375 09/01/2028 | 10-Q: FY2025 Q2 Revenue: USD 797.4 M